Literature DB >> 19689303

HPV as a model for the development of prophylactic and therapeutic cancer vaccines.

Raed N Samara1, Samir N Khleif.   

Abstract

HPV has been linked to many human malignancies and, as such, represents a major public health crisis. The understanding of HPV biology, however, has helped tremendously in developing prophylactic vaccines, which should help in decreasing mortality due to HPV infections. Understanding HPV biology has allowed researchers to use the virus as a model for the development of not only prophylactic vaccines, but also therapeutic ones. The advantages of HPV as a model stem from the limited number of proteins encoded by the HPV genome that can be targeted by vaccines, and also from the restricted expression of certain viral proteins during different stages of infection. In this review, we discuss how HPV can be used as a model for the development of both prophylactic and therapeutic vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689303      PMCID: PMC6948838          DOI: 10.2174/156652409788970625

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  63 in total

Review 1.  The papillomavirus E2 proteins: structure, function, and biology.

Authors:  Rashmi S Hegde
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001-10-25

2.  Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

Authors:  M E Ressing; W J van Driel; R M Brandt; G G Kenter; J H de Jong; T Bauknecht; G J Fleuren; P Hoogerhout; R Offringa; A Sette; E Celis; H Grey; B J Trimbos; W M Kast; C J Melief
Journal:  J Immunother       Date:  2000 Mar-Apr       Impact factor: 4.456

3.  Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia.

Authors:  M Stevenson; L C Hudson; J E Burns; R L Stewart; M Wells; N J Maitland
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

4.  Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

Authors:  R E Royal; S M Steinberg; R S Krouse; G Heywood; D E White; P Hwu; F M Marincola; D R Parkinson; D J Schwartzentruber; S L Topalian; J C Yang; S A Rosenberg
Journal:  Cancer J Sci Am       Date:  1996 Mar-Apr

5.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

Review 6.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

7.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

Review 8.  Immunobiology of HPV and HPV vaccines.

Authors:  Margaret Stanley
Journal:  Gynecol Oncol       Date:  2008-05       Impact factor: 5.482

9.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

Authors:  M A Steller; K J Gurski; M Murakami; R W Daniel; K V Shah; E Celis; A Sette; E L Trimble; R C Park; F M Marincola
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

Review 10.  Chapter 16: Prophylactic human papillomavirus vaccines.

Authors:  Douglas R Lowy; Ian H Frazer
Journal:  J Natl Cancer Inst Monogr       Date:  2003
View more
  2 in total

1.  Therapeutic vaccines for gastrointestinal cancers.

Authors:  Osama E Rahma; Samir N Khleif
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

2.  Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.

Authors:  Osama E Rahma; Vincent E Herrin; Rami A Ibrahim; Anton Toubaji; Sarah Bernstein; Omar Dakheel; Seth M Steinberg; Rasha Abu Eid; Mikayel Mkrtichyan; Jay A Berzofsky; Samir N Khleif
Journal:  J Transl Med       Date:  2014-12-16       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.